Drug Profile
Research programme: antibacterials - BioVersys
Alternative Names: BV-6481Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator BioVersys
- Developer BioVersys; GSK; Lille1 University
- Class Anti-infectives; Antituberculars; Small molecules
- Mechanism of Action Bacterial protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Nosocomial infections; Tuberculosis
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Nosocomial-infections in Switzerland
- 28 Feb 2023 No recent reports of development identified for preclinical development in Tuberculosis in Switzerland
- 29 Oct 2019 Preclinical development for Nosocomial infections and Tuberculosis is ongoing Switzerland